Spear Bio to Unveil Novel Alzheimer’s Disease Immunoassays and Fully Automated Instrument Platform at AAIC 2026

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and

Spear Bio to unveil novel Alzheimer’s disease immunoassays and fully automated instrument platform at AAIC 2026

Spear Bio, an innovator in ultrasensitive protein biomarker detection, today announced plans to unveil new SPEAR immunoassay and instrument innovations at the Alzheimer’s Association International Conference® 2026, taking place July 12–15 in London, UK.

Spear Bio to Release New Alzheimer’s Disease Tests and Automated Instrument Platform

The company is introducing blood-based assays for tau biomarkers and a platform to automate laboratory workflows. Spear Bio announced it will unveil new immunoassays and a fully automated instrument platform at the Alzheimer’s Association International Conference 2026 in London, UK. The launches include a singleplex immunoassay for eMTBR-Tau and an assay for pTau 217 that measures the biomarker across both venous and capillary blood. These tools…